HealthEquity, Inc. (NASDAQ: HQY – Get a rating) has been assigned an average “Buy” recommendation by the fourteen research firms that cover the business, reports MarketBeat Ratings. One analyst has rated the stock with a sell rating and nine have issued a buy rating on the company. The average 1-year target price among brokerages that updated their coverage on the stock in the last year is $77.75.
A number of equity research analysts have recently commented on the company. StockNews.com upgraded HealthEquity from a “hold” rating to a “sell” rating in a Sunday, March 27 research note. Bank of America raised its price target on HealthEquity from $63.00 to $70.00 in a Wednesday, March 23 research note. Wells Fargo & Company launched coverage on HealthEquity in a Monday, April 11 report. They issued an “overweight” rating and a price target of $95.00 for the company. Deutsche Bank Aktiengesellschaft raised its price target on HealthEquity from $66.00 to $67.00 in a report released Wednesday. Finally, BTIG Research upgraded HealthEquity from a “neutral” rating to a “buy” rating and set a price target of $85.00 for the company in a Wednesday, March 30 report.
Large investors have recently increased or reduced their stakes in the stock. Carroll Investors Inc acquired a new position in HealthEquity during Q4 worth approximately $25,000. IndexIQ Advisors LLC purchased a new equity stake in HealthEquity in the fourth quarter for $27,000. Pinebridge Investments LP bought a new position in HealthEquity in the fourth quarter worth $31,000. Signaturefd LLC increased its stake in HealthEquity by 44.3% in the first quarter. Signaturefd LLC now owns 954 shares of the company valued at $64,000 after acquiring 293 additional shares in the last quarter. Finally, Clearstead Advisors LLC bought a new position in shares of HealthEquity during the first quarter worth approximately $65,000. 97.44% of the shares are held by institutional investors and hedge funds.
HQY stock opened at $64.05 on Friday. The company has a market capitalization of $5.40 billion, a P/E ratio of -97.05, a PEG ratio of 5.27 and a beta of 1.08. HealthEquity has a 12-month low of $36.81 and a 12-month high of $84.71. The company has a quick ratio of 2.29, a current ratio of 2.37 and a leverage ratio of 0.50. The company has a fifty-day moving average of $63.45 and a 200-day moving average of $56.09.
HealthEquity (NASDAQ:HQY – Get a rating) last released its results on Monday, June 6. The company reported earnings per share of $0.27 for the quarter, beating analyst consensus estimates of $0.26 by $0.01. HealthEquity posted a positive return on equity of 3.03% and a negative net margin of 7.11%. In the same quarter of the previous year, the company had earned earnings per share of $0.25. As a group, equity research analysts expect HealthEquity to post 0.6 earnings per share for the current fiscal year.
About HealthEquity (Get a rating)
HealthEquity, Inc provides technology service platforms to consumers and employers in the United States. The Company offers cloud-based platforms for individuals to make healthcare savings and spending decisions, pay healthcare bills, compare treatment options and prices, receive benefits personalized and clinical information, earn wellness incentives, increase savings, and make investment choices; and health savings accounts.
This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]
Should you invest $1,000 in HealthEquity right now?
Before you consider HealthEquity, you’ll want to hear this.
MarketBeat tracks Wall Street’s top-rated, top-performing research analysts daily and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market goes viral…and HealthEquity wasn’t on the list.
Although HealthEquity currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
See the 5 actions here